Fair enough, I'm certainly hoping that it does exactly that. But at the least we can all agree that it is still a stopgap, and LEV will not happen with either senolytics or the nutrient sensing pathways. It will be one of the other hallmarks or some third party intervention organ replacement. My money is on epigentics and partial reprogramming. In any case, the argument can be made that we should stop spending so much time on senolytics and sirtuins, and move on a bit to the vanguard. After all, these are becoming mature technologies and I'm convinced they will be mastered in most of our lifetimes. So all we have to do is cautiously but optimistically follow what the many startup companies and research groups are doing and upgrade year-on-year. But as vanguards, the bulk of our energy should be on the cutting edge stuff, not endlessly fine-tuning of established technologies. All that I want left of the senolytics space is a test and that's the only reason I pay attention to this thread. Outside of that, I'm sure the studies will keep rolling in, and within a few years we will have the senescent cell hallmark checked off.
Of course, senescent cells are not the be-all end-all of aging. However, they could be one of the key contributors to aging. At SRF they are currently speculating as to how much senescent cells interact with other types of damage, or how much "cross-talk" there is between different types of aging damage.
Do they (types of aging damage) amplify each other, act in isolation, etc...
Given that senolytics (like fisetin) are relatively cheap, have known and minimal side effects, and are very effective in animal models, it makes sense to me to give them a try, while other therapies are developed.
Edited by Mind, 15 October 2019 - 05:13 PM.